Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Contact

Abraxis BioScience, Inc.
Investors and Media:
Christine Cassiano, 310-405-7417
or
Media:
Claire Campbell, 908-393-8238


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation

Post Your Comments:
(Date:11/30/2009)...N.J. and CHICAGO, Nov. 30 Today at...f the Radiological Society of North America (RSN...d the enrollment of the first patient in an intern...fficacy and safety of florbetaben (BAY 94-9172) PE... in the brain, which are a pathological hallmark o...
(Date:11/30/2009)...BEIJING, Nov. 30 /PRNewswire-Asia-FirstCall/ -- Lo...S) ("Lotus" or the "Company") a growing developer ...tional seller of pharmaceutical,products in the Pe...hat its,Over-the-Counter Drug division ("OTC Divis...ith more than five hundred drug stores in Beijing ...
(Date:11/30/2009)...ORK, Nov. 30 Stemline Therapeutics... company and leading developer of oncology compoun...that The University of Texas M.D. Anderson Cancer ...o a research collaboration. As part of this collab... I/II clinical trial of SL-401 in patients with ac...
Breaking Medicine Technology:Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 2Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 3Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores 2Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores 3Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center 2Gerald A Beathard Fellowship Awarded to Dr Stephen Osaguona 56272 1Gerald A Beathard Fellowship Awarded to Dr Stephen Osaguona 56272 2Gerald A Beathard Fellowship Awarded to Dr Stephen Osaguona 56272 3Boston Scientific to Participate in Thomas Weisel Partners Health Care Conference 56269 1Boston Scientific to Participate in Thomas Weisel Partners Health Care Conference 56269 2263 Regulatory Professionals Achieve RAC Certification 13864 1263 Regulatory Professionals Achieve RAC Certification 13864 2263 Regulatory Professionals Achieve RAC Certification 13864 3
...Results from the Phase II portion of a Phase II/II...g relaxin for the treatment of acute heart failure...rch 29, at the American College of Cardiology,s (A.... , , John R. Teerlink, M.D., professor of medici...ctor of Heart Failure, San Francisco Veterans Affa...
...unced today that,the fourth LNA-based drug has bee...ents with cancer have now been treated with the Co...oped by Santaris Pharma and Enzon,Pharmaceuticals....tly,accepted Enzon Pharma­ceutical,s Investigatio...LNA-based Survivin inhibitor. , Survivin is a ...
Other Medicine Technology:Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session 2Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3
(Date:11/30/2009)... Smoking is on the rise in the developing...e a hard commitment to stop smoking cigarette, but...(E-Cig) can actually help people quit smoking ciga... a site designated to help heavy smokers cut down ... Los Angeles, CA (PRWEB) Nove...
(Date:11/30/2009)...AGO, Nov. 30 Three decades ago, a ...ing swallowed by children, prompting a switch by U...ted today at the annual meeting of the Radiologica...ew tabs are still potentially unsafe. ,, "One o...ge can construction in the U.S. was to eliminate i...
(Date:11/30/2009)... CLEVELAND, Ohio, November 30 Sim...per of medical simulation systems, in collaboratio...Ocedure Rehearsal Studio(TM),workshop for the firs...Germany. , The Simbionix PROcedure Rehear...tor to enable clinicians to create practice scenar...
(Date:11/30/2009)...e-aged men and women who engage in high levels of ...e to their knees and increasing their risk for ost...at the annual meeting of the Radiological Society ...t people with higher physical activity levels may ...es and, thus, at higher risk for developing osteoa...
(Date:11/30/2009)...ge proportion of patients who undergo abdominal/pe...and unnecessary additional image acquisition resul...rding to a study presented today at the annual mee...(RSNA). , "It is the responsibility of all physi...hat the dosage is as low as reasonably achievable ...
Breaking Medicine News(10 mins):Health News:Stop Smoking Cigarette with Electronic Cigarette (E-Cig), Today You Can Quit Smoking Too 2Health News:Beverage Can Stay-Tabs Pose Swallowing Risk 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 3Health News:Too much physical activity may lead to arthritis 2Health News:Unindicated CT series result in unnecessary radiation exposure for patients 2Health News:Unindicated CT series result in unnecessary radiation exposure for patients 3
...ar Admiral Steven K.,Galson, M.D., MPH, Acting Sur...Services (DHHS), will launch a new phase of the Sp...hildhood obesity in the United States,via healthy ... Spot the Block-an,educational outreach campaign t...
...as a tool for investigating abnormal cell prolifer...bor Laboratory (CSHL) has succeeded in clarifying ... light on a way that cancer can begin. , The team...ople, but whose genome contains known oncogenes --...
...reading rumors and gossiping may not cause bruises... of this social type of bullying could linger into...y shows. , In a study of 210 college students, U... according to findings published online this month...
...vides Compliance to a Challenging New Federal ...EACH, Fla., April 22 Sentry Data Systems,Inc. tod...ew feature of its,Sentinel RCM(TM) pharmacy revenu...of Section 6002 of the Federal Deficit,Reduction A...
... women, but rural areas suffer as students choose ...althDay News) -- From 1981 to 2005, the number of ...States fell by more than 25 percent, according to ...les from 1981, 1991, 2001 and 2005. , They found ...
...2 Select Medical,Corporation, a leading provider ...anicsburg, has announced a $2.6 million gift to Ha...he gift is the largest philanthropic investment by...ew 16-story,Academic Center under construction at ...
Other Medicine News:Health News:Scientists discover a mechanism that can send cells on the road to cancer 2Health News:Scientists discover a mechanism that can send cells on the road to cancer 3Health News:Social form of bullying linked to depression, anxiety in adults 2Health News:Social form of bullying linked to depression, anxiety in adults 3Health News:Sentry Data Systems Announces Deficit Reduction Act Compliance Tool 2Health News:Number of U.S. General Surgeons in Decline 2Health News:Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University 2Health News:Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University 3
Nine West Eyewear
MaxMara Eyewear
Liz Claiborne Eyewear
Emporio Armani Eyewear
Medicine Products: